# A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

> **NCT02207829** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1017 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Umeclidinium
- **DRUG:** Umeclidinium matching placebo
- **DRUG:** Tiotropium
- **DRUG:** Tiotropium matching placebo

## Key facts

- **NCT ID:** NCT02207829
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-01
- **Primary completion:** 2015-05-25
- **Final completion:** 2015-06-15
- **Target enrollment:** 1017 (ACTUAL)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207829, "A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02207829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*